The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in Community-Dwelling Elderly People
Abstract
BACKGROUND: Recent reports suggest a possibly protective effect for statins in patients with Alzheimer disease. This association could be due to indication bias, i.e., people who elect to take lipid-lowering agents (LLAs) may be healthier than those who do not, so that it may be these other health factors that explain their lower risk of dementia. OBJECTIVES: To examine the association between the use of LLAs and dementia, adjusting for other markers of health, and to investigate factors associated with LLA use. DESIGN: A cohort study of LLA use and a case-control study of dementia in relation to LLA use, in a secondary analysis of the Canadian Study of Health and Aging. SETTING: A nationally representative population-based survey of Canadians 65 years and older. PARTICIPANTS: To examine features associated with statin use, we evaluated data on 2305 people for whom health information, drug use, and cognitive status were known. To examine the relationship between LLA use and dementia, we selected incident cases of dementia (n = 492, of whom 326 had Alzheimer disease) that occurred between the first and second waves of the study. Control subjects were 823 persons examined during the first and second phases of the Canadian Study of Health and Aging who had no cognitive impairment. RESULTS: Use of LLAs was significantly (P<.001) more common in younger (65-79 years) than in older (> or = 80 years) people. It was not associated with other factors indicating a healthy lifestyle, but was associated with a history of smoking and hypertension. Use of statins and other LLAs reduced the risk of Alzheimer disease in subjects younger than 80 years, an effect that persisted after adjustment for sex, educational level, and self-rated health (odds ratio, 0.26; 95% confidence interval, 0.08-0.88). There was no significant effect in subjects 80 years and older. CONCLUSIONS: While the possibility of indication bias in the original observations cannot be excluded, it was not demonstrated in LLA use in this study. Lipid-lowering agent use was associated with a lower risk of dementia, and specifically of Alzheimer disease, in those younger than 80 years. Further research is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T. D., Rogers, W. J., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430801 · Cited by 1,242
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664
Cited by
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
Midlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238
O'Brien, J. T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., Bowler, J. V., Ballard, C., DeCarli, C., Gorelick, P. B., et al. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00305-3 · Cited by 1,139
Self-citationBrain Cholesterol: Long Secret Life Behind a Barrier
Björkhem, I., & Meaney, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000120374.59826.1b · Cited by 1,044
Alzheimer’s disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 677
(2003) · Neuroepidemiology · doi:10.1159/000072920 · Cited by 672
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Casserly, I., & Topol, E. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15900-x · Cited by 560
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393
Diet and risk of dementia: Does fat matter?: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., van Swieten, J. C., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2002) · Neurology · doi:10.1212/01.wnl.0000038345.77753.46 · Cited by 324
Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease: Preliminary Results
Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., Wasser, D., Johnson-Traver, S., Lochhead, J., & Ziolwolski, C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.5.753 · Cited by 319
Loss of apolipoprotein E receptor LR11 in Alzheimer disease
Scherzer, C. R., Offe, K., Gearing, M., Rees, H. D., Fang, G., Heilman, C. J., Schaller, C., Bujo, H., Levey, A. I., & Lah, J. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1200 · Cited by 316
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Mechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505268200 · Cited by 235
Mixed Dementia—the Most Common Cause of Dementia
KORCZYN, A. D. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04807.x · Cited by 219
Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab208 · Cited by 197
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
Geifman, N., Brinton, R. D., Kennedy, R. E., Schneider, L. S., & Butte, A. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0237-y · Cited by 191
Dyslipidemia and the Risk of Alzheimer’s Disease
Reitz, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0307-3 · Cited by 190
Alzheimer's disease: the lipid connection
Hartmann, T., Kuchenbecker, J., & Grimm, M. O. W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04715.x · Cited by 175
Neuroplasticity in Alzheimer's disease
Teter, B., & Ashford, J. W. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10441 · Cited by 170
Iwagami, M., Qizilbash, N., Gregson, J., Douglas, I., Johnson, M., Pearce, N., Evans, S., & Pocock, S. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00150-1 · Cited by 161
Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits
Tong, X.-K., Lecrux, C., & Hamel, E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0169-12.2012 · Cited by 160
The involvement of lipid rafts in Alzheimer's disease (Review)
Cordy, J. M., Cordy, J. M., Hooper, N. M., & Turner, A. J. (2006) · Molecular Membrane Biology · doi:10.1080/09687860500496417 · Cited by 157
Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease
Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D., Gandy, S., & Hof, P. R. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20155 · Cited by 155
Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK
Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., & Gandy, S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020018 · Cited by 154
Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Vascular Dementia Prevention: A Risk Factor Analysis
Román, G. C. (2005) · Cerebrovascular Diseases · doi:10.1159/000089361 · Cited by 150
Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence
Kivipelto, M., & Solomon, A. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00685.x · Cited by 132
Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases
Wang, Q., Yan, J., Chen, X., Li, J., Yang, Y., Weng, J., Deng, C., & Yenari, M. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2010.04.006 · Cited by 130
Barone, E., Di Domenico, F., Mancuso, C., & Butterfield, D. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.018 · Cited by 127
Circulating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
Increased caveolin-1 expression in Alzheimer’s disease brain
Gaudreault, S. B., Dea, D., & Poirier, J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.07.004 · Cited by 120
Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease
Poirier, J. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00007-8 · Cited by 116
Burgess, B. L., McIsaac, S. A., Naus, K. E., Chan, J. Y., Tansley, G. H. K., Yang, J., Miao, F., Ross, C. J. D., van Eck, M., & Hayden, M. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.007 · Cited by 115
Morley, J. E., & Banks, W. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091576 · Cited by 108
The effects of ABCA1 on cholesterol efflux and Aβ levels in vitro and in vivo
Burns, M. P., Vardanian, L., Pajoohesh‐Ganji, A., Wang, L., Cooper, M., Harris, D. C., Duff, K., & Rebeck, G. W. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03925.x · Cited by 106
Lipid metabolism in Alzheimer’s disease
Liu, Q., & Zhang, J. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1410-3 · Cited by 101
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97
Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E
Fan, J., Donkin, J., & Wellington, C. (2009) · BioFactors · doi:10.1002/biof.37 · Cited by 97
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., & Rosenmann, H. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819ac3cb · Cited by 86
Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease
Reiss, A. B., Siller, K. A., Rahman, M. M., Chan, E. S. L., Ghiso, J., & de Leon, M. J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.009 · Cited by 73
Fong, L. K., Yang, M. M., dos Santos Chaves, R., Reyna, S. M., Langness, V. F., Woodruff, G., Roberts, E. A., Young, J. E., & Goldstein, L. S. B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000441 · Cited by 72
Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease
Chauhan, N. B. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r300010-jlr200 · Cited by 64
Picard, C., Poirier, A., Bélanger, S., Labonté, A., Auld, D., Poirier, J., & on behalf of the PREVENT-AD Research Group (2019) · PLOS ONE · doi:10.1371/journal.pone.0220254 · Cited by 59
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55
Pitavastatin decreases tau levels via the inactivation of Rho/ROCK
Hamano, T., Yen, S.-H., Gendron, T., Ko, L.-W., & Kuriyama, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.020 · Cited by 49
Statins: drugs for Alzheimer’s disease?
Eckert, G. P., Wood, W. G., & Müller, W. E. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0273-1 · Cited by 46
Glöckner, F., Meske, V., Lütjohann, D., & Ohm, T. G. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318212f185 · Cited by 35
Cholesterol and Alzheimer's disease
Wolozin, B. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300525 · Cited by 33
ApoE4: is it the absence of good or the presence of bad?
Ashford, J. W. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4303 · Cited by 21
ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease
Alavez-Rubio, J. S., & Juarez-Cedillo, T. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190823125245 · Cited by 12
Metadata
- Authors
- Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., Wolfson, C., & McDowell, I.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2002-02-01
- Volume
- 59
- Issue
- 2
- Pages
- 223
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2145123193
- Cited by
- 516
- References
- 3
- FWCI
- 30.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.